Page 4 - Linical Evolution News Today

Veeva’s Jim Reilly, vice president is Veeva Development Cloud strategy and along with countless others is getting excited about SCOPE 2024.

Dawn Kaminski is vice president, of business development (BD) operations at eClinical Solutions and is responsible for working with the BD team as a subject matter expert for services and technology, strategically positioning the organization to acquire new business and expand the business offerings within current customers.

Yesterday (January 22), Saama announced the release of several ‘groundbreaking’ features within its AI-driven platform, including generative AI (GenAI) chat and interactive review listings (IRL), that it says create a workflow-driven environment for cross-functional collaboration.

Sano Genetics says it is developing software that will enable ‘the precision medicine revolution’ and has raised $11.4 million in new funding.

Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.

After visiting Biofourmis in Boston last year, OSP was impressed with the remote care the company could offer people from the comfort of their own homes.

Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a €10 million deal.

Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA.

Pharma company Mercaptor has announced its new ‘breakthrough’ technology at J.P. Morgan HealthCare Conference which it says could transform Alzheimer's, TBI, and epilepsy treatment.

Gen Li is president and founder of Phesi. Equally, OSP was delighted to speak to him to discuss the evolution of data management in clinical development and how intelligent data use can reduce clinical trial cancellations, minimise protocol amendments, and accelerate patient recruitment.